BWX Technologies, Inc. (BWXT) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A session indicate strong financial metrics with raised guidance across revenue, EBITDA, EPS, and free cash flow. The Kinectrics acquisition and government/commercial operations show promising growth. Despite some risks, such as lower initial margins and delayed Project Pele delivery, the market strategy with SMRs and medical segment growth is optimistic. The positive sentiment is further supported by the strategic partnerships and opportunities in nuclear energy. Overall, the outlook suggests a positive stock price movement, likely in the 2% to 8% range.
Key Financial Performance
Revenue Third quarter revenue was $866 million, up 29% year-over-year, driven by both Government and Commercial Operations. Excluding contributions from acquisitions, organic revenue was up 12%. The increase was attributed to strong growth in both segments.
Adjusted EBITDA Adjusted EBITDA was $151 million, up 19% year-over-year, driven by robust double-digit growth in Commercial Operations, a modest increase in Government Operations, and lower corporate expense.
Adjusted Earnings Per Share (EPS) Adjusted EPS was $1, up 20% year-over-year, driven by strong operating performance. Nonoperating items were neutral on a net basis.
Free Cash Flow Third quarter free cash flow was $95 million, driven by solid earnings performance and timing of cash receipts from major awards.
Government Operations Revenue Revenue was up 10% year-over-year, driven by Naval Propulsion, Long Lead Material Procurement, Special Materials, and a roughly 3% contribution from the AOT acquisition. This was partially offset by a decline in microreactor volume.
Government Operations Adjusted EBITDA Adjusted EBITDA of $118 million was up modestly compared to last year, resulting in an adjusted EBITDA margin of 19.2%. The modest increase was due to growth in revenue and operational performance.
Commercial Operations Revenue Revenue was up 122% year-over-year, driven by contribution from the Kinectrics acquisition. Organic revenue growth was 38%, driven by strong year-over-year growth in the Commercial Power business and double-digit growth in Medical.
Commercial Operations Adjusted EBITDA Adjusted EBITDA in the segment was $36 million, up 163% year-over-year. This resulted in an adjusted EBITDA margin of 14.2%, driven by solid operational performance and a more favorable mix compared to recent periods.
Backlog Total backlog was $7.4 billion, up 23% from last quarter and up 119% year-over-year. The increase was driven by large multiyear national security contracts for the production of defense fuels and high-purity depleted uranium in the Special Materials line of business.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Microreactors and advanced nuclear technologies: Manufacturing the reactor core for Pele, on track for delivery in 2027. Army announced the Janus program to deploy a nuclear reactor by 2028, with BWXT's qualification as a differentiator.
TRISO nuclear fuel production: Collaboration with Kairos Power to optimize production. Producing TRISO fuel for Project Pele and other customers, with potential for larger commercial market entry.
Special Materials business line: Awarded $1.5 billion defense fuels contract for domestic uranium enrichment and $1.6 billion contract for high-purity depleted uranium supply. Building facilities in Tennessee for these projects.
Commercial Power and SMR sector: Strong demand and expanding opportunities. Signed contract with Rolls-Royce for SMR steam generators and MOU for manufacturing phase. Tracking opportunities in international CANDU life extensions and other large-scale projects.
Operational excellence: Leveraging AI and advanced manufacturing for quality control and workflow efficiencies in Naval Propulsion business.
Capacity expansion: Investing in growth initiatives, including commercial nuclear capacity expansion and smaller government projects.
Strategic petroleum reserve M&O contract: Transitioning to operational control of Canadian Nuclear Laboratories by year-end.
Kinectrics acquisition: Driving revenue growth in commercial nuclear power and medical isotopes, with expanded production capacity for cancer radiotherapy isotopes.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Government Operations: Challenges in meeting delivery commitments for submarine and aircraft carrier programs, requiring intense focus on operational excellence and leveraging advanced technologies to improve productivity and margins.
Special Materials Business: Execution risks associated with long-term projects like the $1.5 billion defense fuels contract and the $1.6 billion high-purity depleted uranium contract, including building new manufacturing facilities and ensuring timely delivery.
Commercial Operations: Pressure on adjusted EBITDA margins due to timing of recovery of higher material procurement costs, particularly in the first half of the year.
Capital Expenditures: Increased capital expenditures (6% of sales) for growth initiatives, including capacity expansion for commercial nuclear and government business, which could strain cash flow.
International Earnings: Higher tax rates expected in 2026 due to a greater percentage of international earnings following the Kinectrics acquisition.
Free Cash Flow: Near-term working capital investments related to significant business growth may lead to flat or slightly higher free cash flow in 2026.
Special Materials Portfolio: Below-average margins in the initial phases of customer-funded CapEx projects for defense fuels and high-purity depleted uranium programs.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
2026 Financial Outlook: BWXT anticipates another year of record financial results in 2026, with low double-digit to low teens adjusted EBITDA growth and high single-digit to low double-digit adjusted earnings per share growth. Free cash flow is expected to be flat to slightly higher due to near-term working capital investments.
Government Operations Revenue Growth: Revenue in this segment is expected to grow in the mid-teens in 2026, driven by growth in Special Materials, Naval Propulsion, and microreactors. Over half of the growth will come from the defense fuels program and high-purity depleted uranium (HPDU) projects.
Commercial Operations Revenue Growth: Commercial Operations is expected to achieve low double-digit organic revenue growth in 2026, with additional contributions from the Kinectrics acquisition. Adjusted EBITDA growth is expected to outperform revenue growth due to favorable mix and solid execution.
Capital Expenditures: Capital expenditures are expected to remain at 5.5% to 6% of sales in 2026, supporting long-term growth initiatives.
Special Materials Projects: BWXT is focused on long-term projects, including a $1.5 billion defense fuels contract and a $1.6 billion contract for high-purity depleted uranium. These projects involve building new manufacturing facilities and are expected to drive significant revenue growth.
Microreactors and Advanced Nuclear Technologies: The reactor core for Project Pele is on track for delivery in 2027. The Army's Janus program, aiming to deploy a nuclear reactor by September 2028, presents additional opportunities for BWXT.
Medical Isotopes and Therapeutics: BWXT Medical expects continued revenue growth in 2026, driven by PET and diagnostic product lines, as well as increasing therapeutic isotope sales for clinical trials. The company is also progressing on tech-99 development for an FDA submission.
Commercial Power and SMR Sector: Demand in the commercial power sector remains strong, with opportunities in CANDU life extensions, new builds, and SMR projects. BWXT recently signed a contract with Rolls-Royce for SMR steam generator design and manufacturing.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Did you book any revenue on the 2 new contracts in the quarter?
A:Very modest contribution, not a big driver. Seasonality around large material procurements shifted some revenue to earlier quarters, causing a large beat this quarter but seasonality in the fourth quarter.
Q:What is BWXT's approach to the Janus program?
A:BWXT intends to compete for the Janus program, which involves reactors at multiple sites. They typically don't own and operate reactors, so they will find the right teammates to pursue the opportunity.
Q:What are the key takeaways from the Kinectrics acquisition?
A:Kinectrics is outperforming, with growth in transmission and distribution, offshore wind cable testing, and life extension programs at the Pickering plant. It also supports licensing for Canadian nuclear utilities' large reactor projects. The medical business is synergistic with BWXT Medical.
Q:Where are the biggest and nearest-term opportunities for BWXT in nuclear energy?
A:Opportunities include small modular reactors (SMRs) in Canada, U.S., Europe, Poland, and the U.K., large reactor builds in Canada, and commercial outlets for TRISO and nuclear medicine. BWXT is actively bidding on AP1000 components and supporting various reactor designs.
Q:How does the revenue cadence roll out for the uranium enrichment and depleted uranium awards?
A:These contracts span 10-15 years with some front-loading for infrastructure investments. Revenue is relatively distributed over the contract period. Initial margins are lower but expected to improve over time.
Q:What is the latest update on Project Pele?
A:The program's delivery is now expected in 2027, later than originally planned due to evolving requirements. The reactor core is being assembled in Lynchburg, Virginia, and will be delivered to Idaho National Laboratory for testing.
Q:Will the capabilities to produce HEU for Naval Propulsion applications require additional funding?
A:The initial funding is for licensing and preparation for the high enriched uranium cascade. Additional funding will be required for material production.
Q:Does the entirety of the 500 grams of ytterbium output belong to BWXT Medical?
A:Yes, it is used as a precursor for lutetium-177. The second-generation EMIS units increased capacity by 500% but have no essential differences from the first generation.
Q:What is the shipset value of the steam generator content won with Rolls-Royce?
A:The value is in the $50 million to $100 million range, but specifics have not been disclosed.
Q:Will BWXT build a manufacturing footprint in Europe for Rolls-Royce reactors?
A:BWXT is evaluating opportunities for localization, which is a trend in commercial nuclear power.
Q:What are the puts and takes on 2026 free cash flow?
A:Improvements in working capital and milestone payments for new contracts are offset by higher CapEx investments. Timing of milestone payments creates variability.
Q:What are the main risks to achieving the 2026 outlook?
A:Risks include timing of commercial nuclear opportunities, defense spending, and an extended government shutdown. Opportunities include operational performance and EAC write-ups.
Q:How does BWXT see the commercial side of nuclear energy playing out?
A:Commercial orders and announcements are expected to accelerate, with SMR and large reactor builds in Canada and the U.S. being key drivers.
Q:What is the status of the DRACO program?
A:The program evolved into NASA's Sentry program with lower funding levels. BWXT is maintaining its team and pursuing lunar efficient surface power opportunities.
Q:What is the opportunity for BWXT in the $80 billion nuclear partnership?
A:The opportunity lies in component manufacturing, such as steam generators and reactor pressure vessels, but specifics are not yet defined.
Q:What is the update on Navy subs and shipbuilding?
A:AUKUS is moving forward, and shipyards are improving production. BWXT is investing in capacity for AUKUS and sees potential opportunities in South Korea's nuclear-powered submarine plans.
Q:Why are government EBITDA margins expected to be down next year?
A:Mix pressure from new contracts with lower initial margins and older pricing agreements are impacting margins. Operational excellence initiatives aim to drive improvement.
Q:Was BWXT supply constrained in the radiopharma business?
A:No, BWXT was not supply constrained for lutetium-177 or its precursor materials.
Q:Will reactor-related RFPs contribute to growth next year?
A:No, reactor-related RFPs will drive backlog but not contribute to growth next year. Growth will primarily come from Bruce and OPG projects in Canada.
Q:What is the status of rare earth handling or processing as a strategic interest for BWXT?
A:Rare earth handling or processing is not a strategic interest for BWXT, apart from specific materials like ytterbium-176.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the specific revenue impact of the $80 billion nuclear partnership, providing only general comments about component manufacturing opportunities without detailed projections or commitments.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AP SMR
Army Janus
BWXT demonstration
BWXT effectiveness
Commercial Power
Government digit
Kinectrics acquisition
Materials line
NNSA
Naval Propulsion
Special Materials
cash generation
centrifuge manufacturing
contribution Kinectrics
control
date
defense fuel
defense purpose
development
digit contribution
end market
future
market demand
microreactors
midpoint
percentage
period
provider market
purity uranium
result backlog
scale
supplier
teen
term outlook
transition
uranium enrichment
BWXT Transcript
BWX Technologies, Inc. (BWXT) Q1 2026 Earnings Call Transcript
Unknown5-5
The earnings call summary presents a mixed picture. While there are positive elements such as strong growth in the Medical segment and unique positioning in TRISO fuel production, there are concerns about delivery risks in nuclear projects and high CapEx. The Q&A section highlights uncertainties, such as unclear timelines for key projects and potential delivery risks, which could weigh on investor sentiment. Without a clear market cap, it's challenging to gauge the exact impact, but the presence of both positive and negative factors suggests a neutral stock price movement.
BWX Technologies, Inc. (BWXT) Q4 2025 Earnings Call Transcript
Positive2-23
The earnings call highlighted strong financial performance with record revenue and significant growth in operating income, net income, and free cash flow. The strategic outlook for 2026 is optimistic, with expectations of continued growth in key segments like government and commercial operations. While there are risks associated with forward-looking statements and reliance on non-GAAP measures, the overall sentiment is positive. The absence of shareholder return plans does not significantly impact the positive outlook due to strong financial metrics and optimistic guidance.
BWX Technologies, Inc. (BWXT) Q3 2025 Earnings Call Transcript
Positive11-3
The earnings call summary and Q&A session indicate strong financial metrics with raised guidance across revenue, EBITDA, EPS, and free cash flow. The Kinectrics acquisition and government/commercial operations show promising growth. Despite some risks, such as lower initial margins and delayed Project Pele delivery, the market strategy with SMRs and medical segment growth is optimistic. The positive sentiment is further supported by the strategic partnerships and opportunities in nuclear energy. Overall, the outlook suggests a positive stock price movement, likely in the 2% to 8% range.
BWX Technologies, Inc. (BWXT) Q2 2025 Earnings Call Transcript
Positive8-4
The earnings call summary shows strong strategic developments, including backlog growth, new contracts, and expansion plans, indicating positive future prospects. The Q&A section reveals proactive measures addressing bottlenecks and strategic partnerships, with analysts showing interest in nuclear and microreactor markets. Despite some uncertainties, the guidance remains optimistic, with a focus on revenue growth and margin expectations. The overall sentiment leans towards positive, suggesting a stock price increase over the next two weeks.
BWXT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
